ClinicalTrials.gg
CompletedNCT00993187Updated Aug 22, 2018Results posted

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

A Phase 4 interventional study of Sitagliptin/Metformin FDC and Comparator: Glimepiride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-22.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
58th of 197
292 · median 102
Started
2010
with 22 others
Phase 4
68 of 198
3 open now
Registered
75th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 58th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 68 in phase 4, and was the 75th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior reduction in HbA1c (mean change from baseline) compared to glimepiride.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has type 2 diabetes mellitus
  • Is currently not on an anti-hypoglycemic agent (AHA) (off for at least 12 weeks) and has a Visit 1/Screening Visit greater than or equal to 7.0% and less than or equal to 9.5%; or is currently on AHA monotherapy or low-dose oral combination therapy (i.e., less than or equal to 50% maximum labeled dose of each agent) and has a Visit 1/Screening Visit HbA1c greater than or equal to 6.5% and less than or equal to 9.0%

Exclusion criteria

Exclusion Criteria:

  • Has a history of type 1 diabetes mellitus or a history of ketoacidosis
  • Has been on any or approved glucagon-like peptide-1 (GLP-1) analogue (such as exenatide, liraglutide, etc.), any investigational or approved dipeptidyl peptidase IV (DPP-4) inhibitor (such as sitagliptin, vildagliptin, alogliptin, etc.) or a peroxisome proliferator-activated receptor (PPAR) gamma agonist agent (such as rosiglitazone, pioglitazone, etc.) within 12 weeks of Visit 1
  • Required insulin within the prior 12 weeks
  • Has a or to any sulfonylurea medication (such as glimepiride, glipizide, etc.), DPP-4 inhibitor (such as sitagliptin, vildagliptin, alogliptin, etc.), or biguanide medication (such as metformin, etc.)
  • Has inadequately controlled hypertension
  • Has cirrhosis or active liver disease
  • Has severe cardiac conditions
  • Is obese
  • Has (HIV)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
292 participants (actual)

Study arms

  • Experimental
    Sitagliptin/Metformin FDC

    Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.

    Drug: Sitagliptin/Metformin FDC · Drug: Matching placebo to glimepiride

  • Active comparator
    Glimepiride

    Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.

    Drug: Comparator: Glimepiride · Drug: Matching placebo to Sitagliptin/Metformin FDC

Interventions

  • DrugSitagliptin/Metformin FDC

    Drug pages: Sitagliptin · Metformin

    Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks

    Also known as: Janumet®

  • Glimepiride tablet orally up to 6 mg daily for 30 Weeks

    Also known as: Amaryl®

  • DrugMatching placebo to Sitagliptin/Metformin FDC

    Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks

  • DrugMatching placebo to glimepiride

    Matching placebo to glimepiride tablet orally daily for 30 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30

    HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline).

    Time frame: Baseline and Week 30

  2. Number of Participants Who Experienced at Least One Adverse Event (AE)

    An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.

    Time frame: Up to 32 weeks

  3. Number of Participants Who Discontinued Study Drug Due to an Adverse Event

    An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.

    Time frame: Up to 30 weeks

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30

    Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline).

    Time frame: Baseline and Week 30

  2. Percentage of Participants With One or More Episodes of Hypoglycemia

    Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required.

    Time frame: Up to Week 30

  3. Change From Baseline in Body Weight at Week 30

    Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline)

    Time frame: Baseline and Week 30

  4. Percentage of Participants With HbA1C < 7.0% at Week 30

    HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%).

    Time frame: Week 30

07

Results

Posted Sep 15, 2014

Participant flow

Participant flow — Overall Study
MilestoneSitagliptin/MetforminGlimepiride
Started147145
Received at least 1 dose of study drug146144
Completed121108
Not completed2637

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1C (HbA1C) at Week 30

HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline).

Time frame:
Baseline and Week 30
Reported as:
Least squares mean · Percent of total hemoglobin
Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30
Percent of total hemoglobinSitagliptin/MetforminGlimepiride
Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30-1.5 (-1.6 to -1.4)-0.7 (-0.8 to -0.6)
Statistical analysis
  • Sitagliptin/Metformin vs Glimepiride · ANCOVA · p = <0.001 · Difference in least squares mean: -0.8 · 95% CI -1.0 to -0.6
PrimaryNumber of Participants Who Experienced at Least One Adverse Event (AE)

An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.

Time frame:
Up to 32 weeks
Reported as:
Number · Participants
Number of Participants Who Experienced at Least One Adverse Event (AE)
ParticipantsSitagliptin/MetforminGlimepiride
Number of Participants Who Experienced at Least One Adverse Event (AE)88101
PrimaryNumber of Participants Who Discontinued Study Drug Due to an Adverse Event

An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.

Time frame:
Up to 30 weeks
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
ParticipantsSitagliptin/MetforminGlimepiride
Number of Participants Who Discontinued Study Drug Due to an Adverse Event88
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 30

Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline).

Time frame:
Baseline and Week 30
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30
mg/dLSitagliptin/MetforminGlimepiride
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30-47.0 (-51.7 to -42.3)-23.5 (-28.2 to -18.8)
Statistical analysis
  • Sitagliptin/Metformin vs Glimepiride · ANCOVA · p = <0.001 · Difference in least squares mean: -23.5 · 95% CI -30.0 to -16.9
SecondaryPercentage of Participants With One or More Episodes of Hypoglycemia

Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required.

Time frame:
Up to Week 30
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Episodes of Hypoglycemia
Percentage of participantsSitagliptin/MetforminGlimepiride
Percentage of Participants With One or More Episodes of Hypoglycemia5.520.1
Statistical analysis
  • Sitagliptin/Metformin vs Glimepiride · ANCOVA · p = <0.001 · Difference in percent: -14.7 · 95% CI -23.0 to -7.0
SecondaryChange From Baseline in Body Weight at Week 30

Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline)

Time frame:
Baseline and Week 30
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight at Week 30
kgSitagliptin/MetforminGlimepiride
Change From Baseline in Body Weight at Week 30-0.83 ± 1.80.90 ± 2.4
Statistical analysis
  • Sitagliptin/Metformin vs Glimepiride · ANCOVA · p = <0.001 · Difference in least squares mean: -1.72 · 95% CI -2.20 to -1.25
SecondaryPercentage of Participants With HbA1C < 7.0% at Week 30

HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%).

Time frame:
Week 30
Reported as:
Number · Percentage of Participants
Percentage of Participants With HbA1C < 7.0% at Week 30
Percentage of ParticipantsSitagliptin/MetforminGlimepiride
Percentage of Participants With HbA1C < 7.0% at Week 3081.240.1
Statistical analysis
  • Sitagliptin/Metformin vs Glimepiride · ANCOVA · p = <0.001 · Difference in percent: 41.01 · 95% CI 30.0 to 51.0

Adverse events

Collected over Up to 32 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin/Metformin—8/146 (5.5%)62/146 (42.5%)
Glimepiride—9/144 (6.3%)54/144 (37.5%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventSitagliptin/MetforminGlimepiride
DUODENAL ULCER HAEMORRHAGEGastrointestinal disorders0/1461/144
INFECTIVE SPONDYLITISInfections and infestations0/1461/144
INFLUENZAInfections and infestations0/1461/144
CONTUSIONInjury, poisoning and procedural complications0/1461/144
OVERDOSEInjury, poisoning and procedural complications0/1461/144
HYPERGLYCAEMIAMetabolism and nutrition disorders0/1461/144
GOUTY ARTHRITISMusculoskeletal and connective tissue disorders0/1461/144
SPONDYLOLISTHESISMusculoskeletal and connective tissue disorders0/1461/144
THYROID CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1461/144
UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1461/144
Most frequent other events
Most frequent other events
EventSitagliptin/MetforminGlimepiride
HYPOGLYCAEMIAMetabolism and nutrition disorders8/14629/144
DYSPEPSIAGastrointestinal disorders19/1469/144
NASOPHARYNGITISInfections and infestations13/14617/144
DIARRHOEAGastrointestinal disorders15/1464/144
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations12/1464/144
NAUSEAGastrointestinal disorders10/1464/144

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sitagliptin/MetforminGlimepirideTotal
Mean54.8 ± 8.553.1 ± 9.253.9 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin/MetforminGlimepirideTotal
Female6661127
Male8184165
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kim SS, Kim IJ, Lee KJ, Park JH, Kim YI, Lee YS, Chung SC, Lee SJ. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. J Diabetes. 2017 Apr;9(4):412-422. doi: 10.1111/1753-0407.12432. Epub 2016 Aug 8. PubMed 27229178 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Oct 2013, 41 months.

Results were first posted in Sep 2014, 10 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 41 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2009
First posted
Oct 12, 2009
StartActual
May 4, 2010
Primary completionActual
Oct 29, 2013
CompletionActual
Oct 29, 2013
Results first posted
Sep 15, 2014
Last update
Aug 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00993187
Responsible party
Sponsor
First posted
Oct 12, 2009
Start date
May 4, 2010
Primary completion
Oct 29, 2013
Completion
Oct 29, 2013
Results posted
Sep 15, 2014
Last update
Aug 22, 2018

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion